This document is a published patent application from Takeda Pharmaceutical Company Limited, identified as US20260085130A1, filed on August 12, 2025. The application details novel anti-Factor XIIa antibodies and their potential use in treating diseases linked to Factor XII activation, plasma prekallikrein signaling, and ocular conditions. The patent application is classified under CPC codes related to antibodies and pharmaceutical compositions.

For compliance officers in the pharmaceutical sector, this represents a new intellectual property filing that may impact future drug development and market exclusivity. While patent applications do not impose direct regulatory obligations, they signal R&D focus areas and potential future therapeutic interventions. Companies operating in related therapeutic areas should monitor the progress of this patent application and its implications for competitive landscapes and potential licensing opportunities.